⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033180 | 0.83 | — | — | |
| SCHEMBL670334 | 0.80 | ALDH1A1 (0.49) | — | |
| SCHEMBL2475700 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL17977369 | 0.69 | FABP6 (0.32) | — | |
| SCHEMBL533758 | 0.69 | MMP12 (0.51) | — | |
| SCHEMBL5800798 | 0.69 | GAA (0.33) | — | |
| SCHEMBL547106 | 0.69 | KDM4E (0.33) | — | |
| SCHEMBL27872 | 0.69 | — | — | |
| SCHEMBL16569936 | 0.68 | OXTR (0.55) | — | |
| SCHEMBL1336591 | 0.67 | ALOX5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | claimed |
| US-20160272617-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | US | claimed |
| US-20160222056-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-04 | — | — | US | claimed |
| EP-3049404-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | claimed |
| EP-3049390-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | claimed |
| WO-2015044165-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | claimed |
| WO-2015044163-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | claimed |
| EP-2833879-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| WO-2013151707-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| CN-117956992-A | MENIN-MLL interaction inhibitors | 赛达克斯制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4337203-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Syndax Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11919901-B2 | Inhibitors of the menin-MLL interaction | SYNDAX PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005004866-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2005-01-20 | — | — | WO | disclosed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |